Modified nusinersen intrathecal injection method: inclusion of a septal needle-free closed infusion connector

OBJECTIVE: Nusinersen, an extremely expensive biologic drug (around 100,000 US$ per dose) that needs to be administered intrathecally, is approved for the treatment of 5q-spinal muscular atrophy (SMA). Because of the low muscle tone of the back muscles of pediatric SMA patients, especially type 1 SM...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yani, Zheng, Kelu, Liang, Cuili, Zheng, Ruidan, Chen, Jinghui, Jiang, Minyan, Zhou, Zhizi, Zhao, Yuan, Rao, Min, Yang, Sida, Chen, Wenxiong, Liu, Li
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Neurology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551161/
https://www.ncbi.nlm.nih.gov/pubmed/37808480
http://dx.doi.org/10.3389/fneur.2023.1234442

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551161/
https://www.ncbi.nlm.nih.gov/pubmed/37808480
http://dx.doi.org/10.3389/fneur.2023.1234442

Ejemplares similares